Apellis Pharmaceuticals to Acquire Potentia Pharmaceuticals.
In PortfolioCRESTWOOD, KY November 20, 2014 – Apellis Pharmaceuticals Inc. Complement inhibition is the only mechanism thus far to show reductions in the growth of dry AMD. Potentia was the first company to develop a complement inhibitor for the treatment of AMD. APL-2 has the same…